Current Controversies and Emerging Data Sets in Follicular Lymphoma and Chronic Lymphocytic Leukemia

CME Information

TARGET AUDIENCE
This activity is intended for medical oncologists, hematologists, hematology-oncology fellows and other healthcare providers involved in the treatment of hematologic cancers.

OVERVIEW OF ACTIVITY
Hematologic oncology and related blood disorders are some of the most rapidly evolving fields in all of medicine. Results presented at major conferences from a plethora of ongoing clinical trials lead to the continual emergence of new therapeutic agents and changes in the indications for existing treatments. In order to offer optimal patient care, the practicing hematologist-oncologist must be well informed of these advances. To bridge the gap between research and patient care, this program uses one-on-one discussion with Dr. Jonathan Friedberg about treatment controversies and the integration of key data sets recently presented into the practical management of follicular lymphoma and chronic lymphocytic leukemia.

LEARNING OBJECTIVES
• Appraise recent data on therapeutic advances and changing practice standards in follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL), and integrate this information, as appropriate, into current clinical care.
• Identify patients with FL who may benefit from maintenance systemic treatment.
• Recall new data with investigational agents demonstrating promising activity in FL.
• Apply the results of emerging clinical research to the selection of optimal systemic therapy for patients with newly diagnosed and relapsed or refractory CLL.
• Identify ongoing clinical trials evaluating innovative investigational approaches for FL and CLL, and obtain consent from appropriate patients for study participation.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component. To receive credit, the participant should watch the video, complete the Post-test with a score of 75% or better and fill out the Educational Assessment and Credit Form located on our website at ResearchToPractice.com/RTPODHem113/CME.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and his spouse/partner) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

Jonathan W Friedberg, MD, MMSce
Samuel Durand Professor of Medicine
Director, Wilmot Cancer Center
University of Rochester
Rochester, New York

Advisory Committee: Genentech BioOncology; Data and Safety Monitoring Board: Lilly USA LLC.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

This activity is supported by an educational grant from Genentech BioOncology/Biogen Idec.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: August 2013
Expiration date: August 2014


Ghielmini ME et al. Long-term follow-up of patients with follicular lymphoma (FL) receiving single agent rituximab at two different schedules in study SAKK 35/98. Proc ASCO 2009;Abstract 8512.

Goede V et al. Obinutuzumab (GA101) plus chlorambucil (Clb) or rituximab (R) plus Clb versus Clb alone in patients with chronic lymphocytic leukemia (CLL) and preexisting medical conditions (comorbidities): Final stage 1 results of the CLL11 (BO21004) phase III trial. Proc ASCO 2013;Abstract 7004.


O’Brien SM et al. A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor idelalisib (GS-1101) in combination with rituximab (R) in treatment-naïve patients (pts) ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (S LL). Proc ASCO 2013;Abstract 7005.


Wiestner A et al. Single agent ibrutinib (PCI-32765) is highly effective in chronic lymphocytic leukaemia patients with 17P deletion. Proc ICML 2013;Abstract 008.

